LIFE : Summary for aTyr Pharma, Inc. - Yahoo Finance

U.S. Markets close in 1 hr 38 mins

aTyr Pharma, Inc. (LIFE)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.55+0.10 (+2.90%)
At close: 4:00PM EST
People also watch
QGENILMNPKIXRAYNWSA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.45
Open3.50
Bid1.60 x 100
Ask3.85 x 100
Day's Range3.50 - 3.55
52 Week Range2.10 - 6.41
Volume51,978
Avg. Volume216,601
Market Cap84.2M
BetaN/A
PE Ratio (TTM)-1.36
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Investopedialast month

    Atyr Pharma Stock Spikes 33% on FDA Updates

    Atyr Pharma said the FDA gave its Resolaris drug fast-track status and lifted a partial hold on a study.

  • PR Newswirelast month

    FDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris

    SAN DIEGO, Jan. 18, 2017 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that its product candidate Resolaris™ was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of limb girdle muscular dystrophy 2B (LGMD2B), making it the first known therapeutic candidate for the treatment of LGMD2B to receive the designation. In addition, the FDA removed its partial clinical hold on a dosing ceiling for Resolaris in clinical trials.

  • Associated Press2 months ago

    Roberts recuses from patent case after discovering conflict

    Supreme Court Chief Justice John Roberts says he will no longer participate in deciding a patent infringement case because he discovered he owns shares in the parent company of one of the parties. Roberts ...